Secondary hyperparathyroidism
Drug research and approvals for secondary hyperparathyroidism: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 22 studies of secondary hyperparathyroidism are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, FDA has 1 approved and 1 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 22
- Trials authorized in Canada: 2
- FDA orphan approvals: 1
- EU medicines: 3
- Bone Deterioration After Kidney Transplantation Assessed by DXA and HR-pQCTNCT07935915 · Not reported · Medical University Innsbruck · starts Oct 21, 2026
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in…NCT07494045 · Phase 2 · OPKO Health, Inc. · starts Aug 5, 2026
- Phosphate Assessment in Chronic Kidney Disease Patients StudyNCT07368946 · Not applicable · University of Texas Southwestern Medical Center · starts May 9, 2025
- The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary RegistrationsNCT07312981 · Not reported · University of Copenhagen · starts Dec 15, 2025
- The CPH-MBD CohortNCT07193056 · Not reported · Herlev Hospital · starts Jan 7, 2026
- The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in…NCT07171216 · Not applicable · Herlev Hospital · starts Nov 20, 2025
- Assessment of Mineral and Bone Disorders in Kidney Transplant RecipientsNCT07141043 · Not reported · Grigore T. Popa University of Medicine and Pharmacy · starts Mar 19, 2025
- Study of MT1013 for the Treatment of Patients With Secondary HyperparathyroidismNCT07122401 · Phase 3 · Shaanxi Micot Pharmaceutical Technology Co., Ltd. · starts Sep 30, 2025
- Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving CinacalcetNCT07007338 · Not reported · Hospices Civils de Lyon · starts Apr 29, 2026
Approved 5
- EtelcalcetideCalcium sensing receptor agonist
- ParicalcitolVitamin D receptor agonist
- CinacalcetCalcium sensing receptor positive allosteric modulator
- DoxercalciferolVitamin D receptor agonist
- CalcifediolVitamin D receptor agonist
Phase 3 3
- EvocalcetCalcium sensing receptor positive allosteric modulator
- Maxacalcitol
- Upacicalcet
Phase 2 5
- DP001Vitamin D receptor agonist
- LunacalcipolVitamin D receptor agonist
- CalcitriolVitamin D receptor agonist
- ASP7991Calcium sensing receptor positive allosteric modulator
- Calcium carbonate
How its trials ended
185 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 52 whose ending is known, 62% met their primary endpoint, 2% missed it and 37% stopped early.
- Completed, result not reported10155%
- Met its primary endpoint3217%
- Ongoing1910%
- Status unknown137%
- Stopped: other or unclear95%
- Stopped: sponsor or business decision53%
- Stopped: enrollment or feasibility32%
- Stopped: funding21%
- Missed its primary endpoint11%
| Mar 26, 2014 | A multicenter single-arm extension study to describe the long-term safety of amg 416 (velcalcetide) in the treatment of secondary hyperparathyroidism in…Amg 416 (velcalcetide) | Amgen | Closed |
| Jun 13, 2013 | A multicenter, multiple-dose, two-arm, active-controlled, double-blind, double-dummy study to compare the therapeutic efficacy and safety of oral doses of…Amg 416 | Amgen | Ongoing |
| Oct 18, 2016 | ZemplarIndicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism… | Abbvie, inc. | Approved |
| Sep 7, 2016 | CinacalcetTreatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease receiving dialysis | Amgen, Inc. | Designated |
| Apr 3, 2020 | Cinacalcet AccordpharmaCinacalcet · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Nov 11, 2016 | ParsabivEtelcalcetide | Amgen Europe B.V. | EMA ↗ |
| Nov 19, 2015 | Cinacalcet Viatris (previously Cinacalcet Mylan)Cinacalcet · generic | Mylan Pharmaceuticals Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA